HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor β-D-2′,3′-dideoxy-2′,3′didehydro-5- fluorocytidine (Reverset™)

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 1, 2003, Pages 49-59

  Geleziunas, Romas ^b   Gallagher, Karen ^c   Zhang, Hangchun ^b   Bacheler, Lee ^d   Garber, Sena ^e   Wu, Jing Tao ^f   Shi, Guoen ^g   Otto, Michael J ^h   Schinazi, Raymond F ^a   Erickson Viitanen, Susan ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Clinical Development   (United States)

^d Tibotec Virco USA   (United States)

^e ASTRAZENECA   (United Kingdom)

^f MILLENNIUM PHARMACEUTICALS INC   (United States)

^g Palatin Technologies   (United States)

^h PHARMASSET INC   (United States)

Author keywords

Multidrug resistance; Nucleoside analogue; Resistance

Indexed keywords

BETA DEXTRO 2',3' DIDEOXY 2',3' DIDEHYDRO 5 FLUOROCYTIDINE; CYTIDINE DERIVATIVE; DIDANOSINE; ELVUCITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG POTENCY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 12444325183     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400105     Document Type: Article

References (31)

1. Balzarini J (1999) Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochemistry & Pharmacology 58:1-27.
2. Bazmi HZ, Hammond J, Cavalcanti SCH, Chu CK, Schinazi RF & Mellors JW (2000) In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrobial Agents & Chemotherapy 44:1783-1788.
3. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schecter M, Schooley RT, Thompson MA, Vella S, Yeni PG, & Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 283:381-390.
4. Carr A., Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, & Cooper D (2000) A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo 1 study. AIDS 14:1171-1180.
5. Coakley EP, Gillis JM & Hammer SM (2000) Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15.
6. De Ronde A, van Dooren M, van der Hoek L, Bouwhuis D, de Rooij E, van Gemin B, de Boer R & Goudsmit J (2001) Establishment of new transmissible and drug sensitive human immunodeficiency virus type I wilt types due to transmission of nucleoside analogue-resistant virus. Journal of Virology 75:595-602.
7. Erickson-Viitanen S, Wu JT, Shi G, Unger S, King R, Fish B, Klabe R, Geleziunas R, Gallagher K, Otto MJ & Schinazi RF (2003) Cellular pharmacology of D-d4FC, a nucleoside analog active against drug-resistant HIV. Antiviral Chemistry & Chemotherapy 14:39-47.
8. Gao W-Y, Agbaria R, Driscoll JS & Mitsuya H (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. Journal of Biological Chemistry 269:12633-12638.
9. Gotte M, Arion D, Parniak MA & Wainberg MA (2000) The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain terminated DNA synthesis. Journal of Virology 74:3579-3585.
10. Hammond JL, Schinazi RF, Chu CK & Mellors JW (2001) Structural features of nucleoside analog reverse transcriptase inhibitors important in selection of resistance mutations in HIV-1 reverse transcriptase. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, Ariz., USA, June 4-9, 2001.
11. Hertogs K, Bloor S, DeVroey V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, van Houtte M, Miller V & Larder BA (2000) A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrobial Agents & Chemotherapy 44:568-573.
12. Hirsch MS (1998) Resistance to antiretroviral drugs - an emerging problem. AIDS 12:6-7.
13. Jadhav P K, Ala P, Woerner FJ, Chang CH, Garber S, Anton EA & Bacheler LT (1997) Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV. Journal of Medical Chemistry 40:181-190.
14. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD & Fiscus SA (2001) Vertical transmission of multidrug resistant human immunodeficiency virus type 1 (HIV-2) and continued evolution of drug resistance in an HIV-1 infected infant. Journal of Infectious Diseases 183:1688-1693.
15. Lee K & Chu CK (2001) Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrobial Agents & Chemotherapy 45:138-144.
16. O'Brien WA (2000) Resistance against reverse transcriptase inhibitors. Clinical Infectious Diseases Suppl. 2:185-192
17. Pastor-Anglada M, Felipe A & Casado FJ (1998) Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends in Pharmaceutical Sciences 19:424-430.
18. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ & Whitcomb JM (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 44:920-928.
19. Rayner MM, Garber S, Logue K, Corbett J, Baker D, Lukac S, Powell D, Bacheler L & Erickson-Viitanen S (2000) Second generation NNRTIs require multiple mutations for selection of highly resistant HIV in vitro. 13th International Conference on AIDS, Durban, South Africa, July 7-12, 2000. Abstract #A347.
20. Schinazi RF, Larder BA & Mellors JW (2001) Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 8:65-81.
21. Schinazi RF, MeUors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, Otto MJ, Stuyver L, Trainor G, Liotta DC & Erickson-Viitanen S (2002) DPC 817: a cytidine nucleoside, analog with activity against zidovudine-and lamivudineresistant viral variants. Antimicrobial Agents & Chemotherapy 46:1394-1401.
22. Shi G, Wu JT, Li Y, Geleziunas R, Gallagher K, Emm T, Olah T & Unger S (2002) Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 16:1092-1099.
23. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropolos C & Whitcomb J (2001) Phenotypic hypersusceptibiity to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 15:1125-1132.
24. Smallheer JM, Otto MJ, Amarl-Ly CA, Earl RA, Myers MJ, Pennev P, Montefiori DC & Wuonola MA (1993) Synthesis and anti-HIV activity of a series of 2-indolinones and related analogs. Antiviral Chemistry & Chemotherapy 4:27-39.
25. Sommadossi JP (1998) Pharmacological considerations in antiretroviral therapy. Antiviral Therapy 3:9-12.
26. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 341:1865-1873.
27. Stein DS & Moore KHP (2001) Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 21:11-34.
28. Van Vaerenbergh K,Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schurman R, Stellbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, DeClercq E, Destmyer J & Vandamme AM (2000) Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrobial Agents & Chemotherapy 44:2109-2117.
29. Winslow DL, Garber S, Reid C, Scarnati H, Baker D, Rayner MM & Anton ED (1996) Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 10:1205-1209.
30. Winslow DL, Stack S, King R, Scarnati H, Bincsik A & Otto MJ (1995) Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Research & Human Retroviruses 11:107-113.
31. Wodarz D & Nowak MA (2000) HIV therapy: managing resistance. Proceedings of the National Academy of Sciences, USA 97:8193-8195.